Table 2. Typical genomic titers (expressed in vg/ml of purified viruses) of AAV constructs used in the study.
| Virus | Capsid | Titer (vg/ml) | Experiment |
|---|---|---|---|
| scCD68-IL6 | AAV6-TM6 | 2.07 E12 | In vivo, in vitro |
| scCD68-GFP | AAV6-TM6 | 1.42 E11 | In vivo, in vitro |
| scF4/80-GFP | AAV6-TM6 | 1.86 E11 | In vivo, in vitro |
| scCBA-GFP | AAV6-TM6 | 1.1 E11 | In vivo, in vitro |
| scCBA-GFP | AAV6-WT | 1.5 E11 | In vitro |
| scCBA-GFP | AAV6-S663V | 1.0 E11 | In vitro |
| scCBA-GFP | AAV6-S663V/T492V | 1.0 E11 | In vitro |
| ssCBA-EGFP | AAV1–9, -rh10 | 1.0 E13 | In vitro |
The different constructs containing GFP or IL-6 transgenes were packaged in different AAV capsids. TM6 refers to a triple-mutant AAV6 capsid (Y731F/Y705F/T492V). All the constructs were used at 1E11/ml following dilution in sterile PBS. AAV, adeno-associated viruses; EGFP, enhanced green fluorescent protein; IL-6, interleukin-6; PBS, phosphate-buffered saline; vg, vector genomes.